2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

2:30PM-4:00PM: Abstract Number: 865

Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

2:30PM-4:00PM: Abstract Number: 850

Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 847

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 818

Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis

3S079: RA – Etiology & Pathogenesis I (815–820)

2:30PM-4:00PM: Abstract Number: 812

Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism

3S077: Pediatric Rheumatology – Basic Science (810–814)

2:30PM-4:00PM: Abstract Number: 810

Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase

3S077: Pediatric Rheumatology – Basic Science (810–814)

2:30PM-4:00PM: Abstract Number: 873

Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database

3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: Abstract Number: 825

Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades

3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: Abstract Number: 878

The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis

3S092: New Approaches to Old Diseases (875–879)

2:30PM-4:00PM: Abstract Number: 868

The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study

3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

2:30PM-4:00PM: Abstract Number: 830

The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 816

The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts

3S079: RA – Etiology & Pathogenesis I (815–820)

2:30PM-4:00PM: Abstract Number: 819

The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts

3S079: RA – Etiology & Pathogenesis I (815–820)

2:30PM-4:00PM: Abstract Number: 823

The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study

3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: Abstract Number: 863

Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial

3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].